CClinical determinants associated with prolonged length of stay in patients hospitalized with multiple myeloma
DOI:
https://doi.org/10.18041/2665-427X/ijeph.2.10163Keywords:
Myeloma Multiple, Cancer Care Facilities, Oncology Service, Length of Stay, Health Service Administration, HospitalAbstract
Introduction: Multiple myeloma is a hematologic cancer associated with low incidence, but high rates of illness and substantial hospital burden for health systems; the importance of identifying factors that may be predictors of prolonged length of stay (LOS) is vital for resource planning, decision-making, and improvement of clinical management in cancer.
Objective: To estimate the clinical determinants that predict prolonged length of stay in hospital admissions of patients with multiple myeloma.
Methods: Analytical observational study of cases and controls, which included patients with Multiple Myeloma hospitalized between 2017 to 2021. Admissions with LOS longer than 14 days (referring to NIH, USA) were identified cases and LOS lower were identified controls. Nominal and categorical descriptive statistics were performed with a multivariate analysis using logistic regression to estimate predictive clinical determinants of prolonged LOS and sensitivity analysis with ROC curve.
Results: Were included 391 hospital admissions with 150 cases and 241 controls, corresponding to 223 patients. Infections (OR: 1.74; IC:1.12-2.71), hydroelectrolytic and metabolic disorders (OR: 2.1; IC: 1.28-3.45), nutritional deficiencies (OR: 2.7; CI: 1.6-4.8), and psychiatric disorders (OR: 20.5; CI: 1.14-3.69) were presented as predictive risk factors for prolonged LOS in hospitalized patients with multiple myeloma.
Conclusion: Infections hydro-electrolyte imbalance, metabolic disorders, nutritional deficiencies and psychiatric disorders were the factors related to prolonged hospital stay.
Downloads
References
Aggarwal S, Kumar S, Topaloglu O. Hospitalization lenght of stay and costs in patients with multiple myeloma: analysis of us national in-patient data for 2015. Value in Health. 2018; 21: S34. DOI: 10.1016/j.jval.2018.04.219
Gonzalez-McQuire S, Yong K, Leleu H, Mennini FS, Flinois A, Gazzola C, et al. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. J Med Econ. 2018; 21(5): 450-67. DOI: 10.1080/13696998.2017.1421546
Kolovos S, Nador G, Kishore B, Streetly M, Rabin NK, Chantry AD, et al. Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. J Bone Oncol. 2019; 17: 100243. DOI: 10.1016/j.jbo.2019.100243
Ceballos-Acevedo TM, Velásquez-Restrepo PA, Jaén-Posada JS. Duración de la estancia hospitalaria. Metodologías para su intervención. Rev Gerenc Políticas Salud. 2014; 13(27): 274-95. DOI: 10.11144/Javeriana.rgyps13-27.dehm
Maiese EM, Evans KA, Chu BC, Irwin DE. Temporal trends in survival and healthcare costs in patients with multiple myeloma in the United States. Am Health Drug Benefits. 2018; 11(1): 39-46.
Vakit A, Patel B, Jonnalagadda A, Alhaj M, Shenoy A. Trends of Hospitalization for Multiple Myeloma Patients-Insights from the National Inpatient Sample Database. Clin Lymphoma Myeloma Leukemia. 2018; 18: S245. DOI: 10.1200/JCO.2018.36.15_suppl.e20015
Pineli M, Amigo C, Alvarado CA, Figueroa R, Bucheli E. Multiple myeloma: burden of disease analysis in some countries of latin america. Oncol Clín. 2018; 23(1): 27-34. DOI: 10.56969/oc.v23i1.67
Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016; 43(6): 676-81. DOI: 10.1053/j.seminoncol.2016.11.004
Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018; 4(9): 1221-7. DOI: 10.1001/jamaoncol.2018.2128
Dumontet C, Couray-Targe S, Teisseire M, Karlin L, Maucort-Boulch D. Real life management of patients hospitalized with multiple myeloma in France. PLoS One. 2018; 13(5): e0196596. DOI: 10.1371/journal.pone.0196596
Bravo LE, Garcia LS, Collazos P, Carrascal E, Grillo-Ardila EK, Millan E, et al. Cancer epidemiology in Cali, 60 years of experience. Colomb Med (Cali). 2022; 53(1): e2005050. 10.25100/cm.v53i1.5050
Segovia J, Duarte M, Restrepo JG, Saavedra CE, Andrade RE. Mieloma múltiple en el Hospital Universitario Fundación Santa Fe de Bogotá (1983-2006). Acta Méd Colomb. 2008; 33(4): 276-81.
Asociación Colombiana de Hematología y Oncología (ACHO); Fundación Universitaria de Ciencias de la Salud. Guía de Práctica Clínica para el tratamiento del mieloma múltiple. Bogotá, Colombia; 2020 Disponible en: https://www.fucsalud.edu.co/sites/default/files/2020-06/GPC-MIELOMA-MULTIPLE-V-PROFESIONAL-salud.pdf
Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Hemasphere. 2021; 5(2): e528. DOI: 10.1016/j.annonc.2020.11.014
Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. British J Haematol. 2007; 138(5): 563-79. DOI: 10.1111/j.1365-2141.2007.06705.x
Park H, Youk J, Kim HR, Koh Y, Kwon JH, Yoon SS, et al. Infectious complications in multiple myeloma receiving autologous stem cell transplantation in the past 10 years. Int J Hematol. 2017; 106(6): 801-10. DOI: 10.1007/s12185-017-2313-2
Yilmaz M, Atilla FD, Sahin F, Saydam G. The effect of malnutrition on mortality in hospitalized patients with hematologic malignancy. Support Care Cancer. 2020; 28(3): 1441-8. DOI: 10.1007/s00520-019-04952-5
Lee DH, Fung TT, Tabung FK, Marinac CR, Devore EE, Rosner BA, et al. Prediagnosis dietary pattern and survival in patients with multiple myeloma. Int J Cancer. 2020; 147(7): 1823-30. DOI: 10.1002/ijc.32928
Greenfield DM, Boland E, Ezaydi Y, Ross RJM, Ahmedzai SH, Snowden JA, et al. Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma. Bone Marrow Transplant. 2014; 49(7): 907-12. DOI: 10.1038/bmt.2014.63
Borsi E, Serban CL, Potre C, Potre O, Putnoky S, Samfireag M, et al. High carbohydrate diet is associated with severe clinical indicators, but not with nutrition knowledge score in patients with multiple myeloma. Internat J Environm Res Public Health. 2021; 18(10): 5444. DOI: 10.3390/ijerph18105444
Hagiwara S, Mori T, Tuchiya H, Sato S, Higa M, Watahiki M, et al. Multidisciplinary nutritional support for autologous hematopoietic stem cell transplantation: A cost-benefit analysis. Nutrition. 2011; 27: 1112-7. DOI: 10.1016/j.nut.2010.11.010
Han X, Lin CC, Li C, de Moor JS, Rodriguez JL, Kent EE, et al. Association between serious psychological distress and health care use and expenditures by cancer history. Cancer. 2015; 121(4): 614-22. DOI: 10.1002/cncr.29102
Niazi S, Frank RD, Sharma M, Roy V, Ames S, Rummans T, et al. Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma. Blood Adv. 2018; 2(10): 1120-8. DOI: 10.1182/bloodadvances.2018016717
Stiefel FC, Breitbart WS, Holland JC. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest. 1989; 7(5): 479-91. DOI: 10.3109/07357908909041378
Vanstechelman S, Vantilborgh A, Lemmens G. Dexamethasone-induced catatonia in a patient with multiple myeloma. Acta Clin Belg. 2016; 71(6): 438-40. DOI: 10.1080/17843286.2016.1146442
Copeland A, Freeman A, Baggett C, Zhou L, Shea TC, Tuchman SA, et al. Prevalence of depression and anxiety in older patients with multiple myeloma in North Carolina: A population-based, claims-based assessment. J Clin Oncol. 2017; 35(15 suppl): 10048-10048. DOI: 10.1200/JCO.2017.35.15_suppl.10048
Ribeiro‐Carvalho F, Gonçalves‐Pinho M, Bergantim R, Freitas A, Fernandes L. Trend of depression and its association with sociodemographic and clinical factors among multiple myeloma hospitalizations: A Portuguese nationwide study from 2000 to 2015. Psycho‐Oncology. 2020; 29(10): 1587-94. DOI: 10.1002/pon.5469
Gavriatopoulou M, Paschou SA, Ntanasis-Stathopoulos I, Dimopoulos MA. Metabolic Disorders in Multiple Myeloma. Int J Mol Sci. 2021; 22(21): 11430. doi: 10.3390/ijms222111430.
Huang HY, Wang Y, Wang WD, Wei XL, Gale RP, Li JY, et al. A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma. Leukemia. 2021; 35(11): 3212-3222. doi: 10.1038/s41375-021-01206-4.
Anandan A, Kolk M, Ferrari N, Copley M, Driscoll J, Caimi P, Rashidi A, de Lima M, Malek E. Serum electrolyte dynamics in multiple myeloma patients undergoing autologous haematopoietic stem cell transplantation. Nephrol. 2020; 25(6): 450-456. doi: 10.1111/nep.13712.
Downloads
Published
Versions
- 2023-12-30 (4)
- 2024-04-22 (3)
- 2024-04-19 (2)
- 2023-12-30 (1)
Issue
Section
License
Copyright (c) 2023 Interdisciplinary Journal of Epidemiology and Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
NonCommercial — You may not use the material for commercial purposes.
-
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
